Addressing challenges through the rigorous application of science
Our platform creates high-quality, affordable RNA at scale
Messenger RNA for human health
Sustainable food production through RNA solutions
Scaling biology in the service of humanity
A diverse, compassionate, and qualified team
Working at GreenLight
Collaborating with GreenLight
RNA can help tackle some of humanity’s greatest problems
Our product pipeline is sustainable by design and produced in a responsible manner.
Our business model aims to improve lives across all geographies.
One of the world’s first publicly traded public benefit corporations
Sign-up for our Newsletter
To address unmet medical needs of underserved populations and to prepare for future pandemics, we work with every part of the world to advance the discovery, development, scale-up, and manufacturing of vaccines and therapeutics.
We aim to make RNA products more accessible to low- and middle-income countries and believe that local needs are best addressed when we partner locally from the very beginning of the product research and development process.
In our plant health development process, we are committed to engaging with local agencies, agricultural partners, and academic institutions to create solutions to protect regional crops from relevant pests.
We are establishing a global network of partnerships and workforce development to advance research and manufacturing of effective and selective solutions targeting local pests.
We actively seek to partner with local companies in Africa, Asia, and Latin America to advance equitable access to messenger RNA vaccines and therapeutics targeting regionally prevalent diseases.
These partnerships aim to develop skills and capabilities to research, develop, make, and commercialize messenger RNA products.
We continuously work to improve our representation of gender, race, and ethnicity at all levels, including our board, VP, and executive levels.
Full-time employees
*Figures as of December 31, 2022
46% of our full-time employees self-identify as female.*
46% of our full-time employees identify as a member of a non-Caucasian racial or ethnic group.*
Executive Team
*Figures as of April 1, 2023
60% of GreenLight’s executive team members are female.
30% of our executive team identifies as a non-Caucasian racial or ethnic group.*
Board of Directors
*Spencer Stuart, 2022 **Figures as of December 31, 2022
57% of board members are racially and ethnically diverse.**
29% of GreenLight’s board members are female.**
*MassBio Report, 2021 **Figures as of April 1, 2023
60% of the executive team are female.**
Research and Scientist positions
*US Census, 2021 **Figures as of December 31, 2022
42% of employees in research and scientist positions are female.**
Our culture is built on care, transparency, employee ownership, and a deep, humble respect for science.
The representation of women across GreenLight has increased over the past year. As of March 2023, women now make up 47% of all employees (up from 45% in March 2022).
Our representation of ethnic and racial minorities has remained stable at 45% over the last year.
We regularly measure and share with employees information about our gender pay gap and company statistics.
Our employee-run resources groups focus on common priorities and areas of interest, including the LGBTQ+ community, women, community service and fundraising, wellness, and equity, diversity & inclusion.